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Abstract: Liquid Chromatography Time-of-Flight Mass Spectrometry (LC-TOF) utilizes a high-
resolution mass spectrometer and chromatography to identify drugs in urine, based on their exact 
masses and retention times. The current “gold standard” method of qualitative urine drug 
screening is the immunoassay, which uses antibodies developed against drugs or their metabolites 
to identify them. Since this antibody-based methodology may have significant cross-reactivities 
and loss of specificity associated with it, it has been proposed to replace it with LC-TOF. This 
research compares the detection of drugs in urine with immunoassay and LC-TOF, following the 
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The use of prescribed drugs to combat pain has become common in the United States. 
This pain management, unfortunately, has a high chance of turning into an addiction. Urine drug 
testing currently is the best way to determine compliance with the prescribed drug regimen from 
doctors. To perform urine drug testing, the urine sample must go through two stages: screening 
and confirmation.  
Urine screening is commonly performed on an immunoassay instrument. In this research, 
the immunoassay instrument used is called EasyRA®. It is a clinical chemistry analyzer produced 
by Medica. Immunoassays work by using antibodies specific to drug classes and using them to 
interact with drugs present in urine.  
Urine specimens that are screened with immunoassay are typically sent for confirmatory 
testing. Confirmation testing is used to definitively state there are certain substances present and 
at what concentration. Confirmation testing in this laboratory is done on a liquid chromatography-




laboratory. Samples analyzed by LC/TOF in this research were previously screened by 
immunoassay and quantitatively confirmed using LC-MS/MS. 
The high-resolution mass spectrometer used was the AxION® 2 Time-of-Flight Mass 
Spectrometer (LC-TOF) from PerkinElmer. This instrument has the ability to calculate accurate 
mass measurements. Accurate mass is defined as the “experimentally determined mass of an ion 
to an appropriate degree of accuracy used to determine the elemental formula of the ion” 
(Brenton, 2010). In this instance, the LC-TOF can identify an analyte based on its mass carried 
out to four decimal places. This ability ensures the certainty that what has been identified is 
correct because of the specificity of the mass. However, the analyst must be aware that this 
technique does not take into account isobars, or analytes which have identical masses because 
they have identical formulas, such as Codeine and Hydrocodone. 
The samples used in this research were also run on the LC-MS/MS to verify the working 
order and abilities of the LC-TOF. Because the LC-MS/MS has a validated method, it is 
considered the “gold standard” of quantitation. Therefore, the samples’ results from each 
instrument will be compared to each other. If both instruments produce the same results, it can be 
said the LC-TOF is a viable instrument for urine drug screening.  
Method validation was conducted on this instrument including matrix effects, 
interference, sample stability, and limit of detection. In addition, robustness, sensitivity, and 
specificity of the instrument were determined.  
This research can be used to determine if the immunoassay method being used now is 
truly the best method or if there is something else on the market which can do the same job with 
more specificity, more sensitivity, and more cost and time efficiently. LC-TOF can also be used 







REVIEW OF LITERATURE 
 
2.1 Introduction 
Pain management is becoming increasingly prevalent in the United States. Chronic pain 
is found in a large portion of the adult population. Unfortunately, the drugs prescribed to combat 
this issue are at a high risk of causing addiction or drug abuse. Urine drug testing has become the 
best way to determine compliance or noncompliance with the prescribed drug regimen. It is often 
found that some of those who take pain medication also take illicit drugs as well. Some of these 
drugs are known as novel psychoactive substances and need to be identified and characterized to 
determine usage legalization issues. However, these drugs are difficult to identify. There are two 
main instruments currently being used to identify analytes in urine samples, gas chromatography 
mass spectrometry and liquid chromatography-tandem mass spectrometry. There has been an 
emergence of another instrument, liquid chromatography time-of-flight mass spectrometry, that 
may be superior to the previous instrumentation. 
2.2 Urine Drug Testing in the Clinical Setting 
Chronic pain is generally found in about 2% to 40% of the adult population (Cone, 2008). 
These patients are often maintained on one or multiple strong pain medications such as opioids
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and benzodiazepines (Cone, 2008). This trend has increased over the past decade (Christo 2011). 
Unfortunately, these prescribed medications are at a high risk of addiction and abuse (Christo 
2011). To help with combatting these developments, urine drug testing has become more often 
used in the medical field. Urine drug testing (UDT) has the ability to identify use of prescription 
drugs in order to track compliance. It can also identify non-prescribed or illicit drugs to help deter 
and/or treat possible abuse (Cone 2008, Christo, Heit 2004, Florete 2012). It has been found that 
many pain medication patients also self-administer illicit drugs. In a study completed with 10,922 
pain patient specimens, 1195 (10.9%) were found to have various combinations of illicit drugs 
(Cone, 2008). UDT also helps provide proper drug therapy for individual patients (Christo). 
Christo et al. mentioned a study of almost a million pain patients who were urine drug tested. The 
results showed that 75% of patients were unlikely to be taking their pain medications with the 
prescribed regimen, 38% were found to have no detectable amount of prescribed medication in 
their system, 29% had non-prescribed medication in their system, 27% had concentrations lower 
than expected, 15% had concentrations higher than expected, and 11% had illicit drugs present 
(Christo 2011). Being able to identify these issues with UDT has allowed the doctors to know of 
these issues and to help the patients.  
Positive results of prescribed drugs relay to the doctor and the patient that the patient is 
following the treatment plan (Heit, 2004). A positive result of a non-prescribed drug or illegal 
drug can help the doctor to identify, discuss, and treat the possibility of abuse or misuse (Heit, 
2004). Detection, identification, and analysis of drug metabolites is essential in UDT because 
along with the parent drug, it indicates use of the drug (Plumb, 2003). Metabolites are also 
important because sometimes the parent drug concentration is below a detectable concentration or 
not present at all (Plumb, 2003). 
Urine is used for many reasons instead of blood or serum. Collection is non-invasive, the 
specimen provides plenty of volume, drugs and their metabolites are usually present in higher 
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concentrations and for longer periods of time than in other specimens, the sample is easily 
preserved by refrigeration or freezing, and the testing is relatively cost effective (Heit, 2004, 
Lum, 2004). While urine is ideal for drug testing, it does have some disadvantages. Adulteration 
of the sample is possible if the individual is trying to avoid detection. Adulteration occurs when a 
patient adds to the sample, dilutes the sample, or uses another’s urine as their own to avoid 
detection of drug use. Collection observation is not usually performed making adulteration or 
replacement of urine an issue. Urine also varies in dilution which can make false-negative results 
a possibility (ARUP, 2018). 
Historically, there have been multiple methods utilized for UDT. Urine must first be 
screened to determine what drug classes may be present in the urine. This is typically carried out 
by immunoassay testing which are designed to find the classes present or absent in the specimen 
(Heit, 2004). Immunoassay tests use antibodies to identify and measure chemical substances, in 
this case, drugs. The antibodies, which are the body’s response to a foreign substance, are created 
by animals that have the drug of interest injected into them. Antibodies that specifically bind to 
the drug are produced in a serum which is then collected. Isotopically labeled drugs are mixed 
into the serum and compete with unlabeled drug for the antibody binding sites. These tests work 
by comparing the amount of an isotopically labeled drug bound to the antibody against a 
reference standard that contains a known concentration. A higher concentration of drug in the 
tested sample will displace a large amount of the labeled drug while a lower concentration would 
displace less. This methodology is applied to unknown samples for identification.  
A drawback of immunoassay is the low specificity and cross reactivity. Specificity refers 
to the ability of an assay to correctly identify the drug of interest. Cross reactivity refers to the 
response of the assay to substances other than what it was designed to respond to. The antibody 
will not bind with dissimilar structures to the specific drug, but will bind to structures similar to 
the drug (Levine, 2015). For example, the antibody assay for amphetamine will have the ability to 
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bind with methamphetamine, phentermine, and MDMA. Immunoassay also has the possibility to 
miss adulterated samples from those who are trying to hide what is in their urine samples.  
Immunoassay tests identify drug classes instead of individual drugs because of the cross 
reactivity and specificity. These classes may include: amphetamines, barbiturates, 
benzodiazepines, cannabinoids, carisoprodol, cocaine, ecstasy, fentanyl, meperidine, methadone, 
opiates, oxycodone, and propoxyphene (Cone, 2008). After screening, the specimens that were 
found to be positive for one or more drug classes must go through confirmation testing (Cone, 
2008, Heit, 2004). Confirmation testing is a secondary test by a different chemical method to 
positively identify an analyte (Lum, 2004). It is used to determine what specific drug caused the 
screen to be positive for a certain drug class and at what concentration that drug is in the urine 
(Heit, 2004). This type of testing is usually carried out by gas chromatography mass spectrometry 
(GC-MS) or liquid chromatography tandem mass spectrometry (LC-MS/MS).  
In previous years, GC-MS has been considered the “gold-standard” for drug analysis 
because it provides the most accurate results (Lum, 2004). The GC-MS volatizes a liquid sample 
which then travels through a column to separate the components. The time at which the 
components exit the column is known as the retention time and is used in identification of the 
analyte. Those components are then analyzed in the mass spectrometer to determine what 
components are present and at what concentrations (Skoog, 2007). GC-MS software contains a 
database that compares the results to already confidently identified analytes for further 
confirmation. A limitation to this instrumentation for drug analyses is that GC-MS can tend to 
give false-negatives (Pelander, 2003). A false-negative is possible if the drug is susceptible to 
thermal decomposition due to the extensively high temperatures produced in the instrument 
(Fessessework, 2013). GC-MS is still rather popular and is used today in many laboratories.  
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More recently, the liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
instrumentation has been used for drug analysis. The LC-MS/MS uses liquid chromatography for 
separation. This is accomplished by using a solid phase column. When the solution is sent 
through the column, the ions will have some degree of affinity to it and stick to the column. To 
release these ions, aqueous and organic mobile phases are sent through the column to release the 
ions. The greater the affinity of the ion, the greater the percentage of the corresponding mobile 
phase is needed. The time the ion is released and comes off of the column is referred to as the 
retention time (Skoog, 2007). 
These components are then sent through a triple quadrupole mass spectrometer. A 
quadrupole mass spectrometer contains four rods that only allow an analyte with a single m/z to 
pass through. A triple quadrupole contains three of these sets of rods referred to as Q1, Q2, and 
Q3. The triple quadrupole selects parent ions of a specific m/z in the Q1 which are then sent to 
the Q2. The Q2 applies a voltage and a collision gas to cause ion collision and fragmentation of 
the parent ions. These fragmentations, or product ions, are sent on to the Q3 to select the 
fragmented ions desired. The product ions are sent to the detector to be identified and quantified 
(Skoog, 2007). Figure 1 shows an example setup of a triple quadrupole mass spectrometer. The 
multiple quadrupoles are why the instrument is referred to as “tandem.” LC-MS/MS is sensitive, 
specific, and can be programmed to detect an abundance of drugs. Unfortunately, one must 
instruct the instrument to look for specific ion transitions and fragmentation. An LC-MS/MS will 
find what it is told to scan for and disregard the rest of the ions (Fessessework, 2013). LC-
MS/MS is utilized in many laboratories. While this instrumentation is commonly used for 
confirmatory testing, it can be used a general screening tool. However, LC-MS/MS has the 
disadvantage of the restricted number of target compounds that can be included in an assay as 
well as the requirement of method development and revalidation of existing analytes after a new 




Figure 1.Triple quadrupole mass spectrometer. (Taken from Ni J, Ouyang H, Aiello M, 
et al. Microdosing Assessment to Evaluate Pharmacokinetics and Drug Metabolism in 
Rats Using Liquid Chromatography-Tandem Mass Spectrometry. Pharm Res. 
2008;25(7):1572-1582. doi:10.1007/s11095-008-9555-x) 
2.3 LC-TOFMS in the Clinical Setting  
While GC-MS and LC-MS/MS are still being used regularly in clinical laboratories, there 
are newer, more sensitive instruments on the market. One of these instruments, the liquid 
chromatography time-of-flight mass spectrometer (LC-TOF) is becoming increasingly popular 
based on multiple published methods (Fessessework, 2013). LC-TOF uses the same principles as 
LC-MS/MS but uses the amount of time each molecule takes to reach the detector to identify the 
analyte (Skoog, 2007). After separation of the ions through liquid chromatography, the ions have 
a voltage applied to them and are sent through a drift tube which is under vacuum. The ions travel 
through the drift tube until they reach a reflectron which reflects the ions back down the tube 
towards the origin of the voltage and the detector. The ions will reach the detector based on the 
amount of time it takes the ion to reach it. Heavier ions travel slower than lighter ions and 
therefore reach the detector at a later time than the lighter ions. Error! Reference source not 
found. displays a diagram of this process. LC-TOF uses this time along with the retention time 




Figure 2. Diagram of time-of-flight mass spectrometer mechanism. (Taken from 
http://what-when-how.com/proteomics/time-of-flight-mass-spectrometry-proteomics/ 
LC-TOF is known for its accurate mass capacity (Ojanpera, 2006).  Accurate mass is 
defined as “the experimentally determined mass of an ion measured to an appropriate degree of 
accuracy and precision used to determine, or limit the possibilities for, the elemental formula of 
the ion” (Brenton, 2010). The accurate mass capacity of the LC-TOF includes its ability to 
identify an analyte based on its mass of up to four decimal places ensuring confidence in the 
identification of the analyte. It also has high resolving power which is used to separate peaks, 
assign the peak centroid, and reduce ambiguity (Ojanpera, 2012). An LC-TOF not only has the 
ability to identify known analytes used in conjunction with reference standards, but also has the 
ability to identify unknown analytes without reference standards by being used as a screening 
instrument (Pelander, 2003). LC-TOF utilizes a calibration solution that contains analytes for lock 
masses. Lock masses are used to calibrate the instrument before and during use. The constant 
flow of the lock mass components in the calibration solution allows for real-time recalibration of 
mass accuracy by correcting any sources of measurement error that may be encountered 
(Chindarkar, 2015). This internal calibration during analysis to also assures no peak drift 
(Ojanpera, 2012). LC-TOF has greater selectivity, sensitivity, and speed when compared to GC-
MS and LC-MS/MS (Ojanpera, 2012).  
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In a study done by Fessessework et al., a screening method for drugs and metabolites was 
validated using an LC-TOF (Fessessework, 2013). In the publication, it discusses the difficulties 
with new drugs that are available. Current methods are not easily adaptable and it takes a lot of 
work to constantly and consistently develop a new method for each new drug that comes onto the 
market. It was determined that an LC-TOF can screen and identify a multitude of drugs and their 
metabolites on demand without having to create or add to a working method. Also, adding a new 
analyte to a method does not require re-validation of current drugs when new ones are added like 
with LC-MS/MS (Partidge, 2018). This, as Fessessework stated, can lead to faster confirmations 
and turnaround times. This instrument can conduct an all-scan at all times to identify target 
knowns as well as retrospective searching for compounds that are not yet sought after. Screening 
with an LC-TOF allows for selective, rapid, and specific determination of target compounds and 
those unknown (Fessessework, 2013). 
 In other studies, urine drug testing results from an LC-TOF were compared to those of a 
GC-MS and an LC-MS/MS. Identification with the LC-TOF was based on accurate mass and 
retention time (Saleh, 2012). It was found that the LC-TOF had a higher number of compounds 
identified compared to the GC-MS along with no false negatives except for caffeine (Pelander, 
2003). When compared to the LC-MS/MS, it had a lower false positive and false negative rate 
(Saleh, 2012). Both studies found the LC-TOF to be an excellent instrument in the clinical 
setting. A conductor of one of these studies, A. Saleh, agreed with Fessessework et al. in that a 
new screening technique for new drugs on the market is necessary and the LC-TOF is a good 
candidate for this job (Saleh, 2012).  
2.4 Screening for Novel Substances 
There is an array of drugs that urine pain management samples are analyzed for. These 
tend to be the drugs included in the drug classes mentioned before for urine screening. However, 
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recently there has been a demand for the screening of novel psychoactive substances, or NPS. 
These substances are newly created drugs or currently used drugs being used in new or “novel” 
ways (Orsolini, 2016). NPS are sold as legal highs, bath salts, plant food, and air fresheners that 
are disclaimed as “not for human consumption” to avoid legislation (Orsolini, 2016). They can be 
purchased online or in head shops that sell smoking accessories (Orsolini, 2016). As of 2016, it 
was determined that synthetic cathinones and cannabinoids as well as psychedelics and 
phenethylamines account for the largest number of NPS being used (Orsolini, 2016). There is 
now an “online drug culture” that has increased the availability of NPS (Orsolini, 2016). With the 
rapid development of new NPS, a urine screening method needs to be implemented to determine 
the use of them.  
Because NPS are so quickly created, sold, and retired, there is no time for current 
methods to be modified or created to adapt to these substances. Quantification methods may not 
be required to be developed due to the fact that once compounds become regulated, new and 
sometimes more potent analogues are developed in order to avoid the law and increase 
psychoactive effects (Zawilska, 2015). This is when the LC-TOF becomes superior to previous 
methods. It is already known that the LC-TOF has the capability of identifying known and 
unknown analytes (Fessessework, 2013). It provides accurate mass and retention times of 
complex samples. The LC-TOF can operate at a constant all-scan which can identify the known 
analytes as well as the unknowns (Fessessework, 2013). It can complete these scans at practically 
an unlimited mass range meaning it would be able to characterize analytes without having to 
know the mass (Skoog, 2007). Due to its abilities, there have been screening methods created 
already on the LC-TOF for the everyday drugs looked for in urine analysis (Fessessewoek, 2013). 
However, there is need of a method that can accurately identify and potentially quantify NPS.  
There are some NPS that are currently on many laboratories’ analyte lists. These include 
3,4-Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 
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also known as Eve, 3,4-Methylenedioxymethamphetamine (MDMA) also known as ecstasy, 
phencyclidine (PCP), fentanyl, norfentanyl, acetyl fentanyl, and acetyl norfentanyl along with 
other fentanyl analogues. Other drugs that may not be as common include analogues for 
phenethylamine, ketamine, and cathinones (Zawilska, 2015). Drugs such as these are likely being 
quantified in laboratories because they have been around for many years and are still prevalent 
today, an attribute that most NPS do not have. LC-TOF is able to conduct quantification methods 
as well as screenings, making it a versatile instrument. It is also possible to run a quantification 
method with a screening method behind it and constantly be looking for substances that the 
operator is unaware of. LC-TOF allows for retrospective data analyses and reprocessing of data 
without re-extraction or repeated instrumental analysis (Fessessework, 2013, Pasin, 2015). If an 
NPS is discovered as being used, previous data can be reprocessed and looked at retrospectively 
to determine if previous samples contain the NPS of concern which can help identify trends and 
around what time the drug began to be used in the area.  
2.5 Conclusion 
Liquid chromatography time-of-flight mass spectrometry is a good choice for an 
instrument for urine drug analysis and urine drug screening. LC-TOF has greater specificity and 
sensitivity as well as not having the issue of cross reactivity as is seen in immunoassay. It has 
multiple abilities that make it superior to immunoassay testing, gas chromatography-mass 
spectrometry and liquid chromatography-mass spectrometry for the same application. Few 
clinical laboratories presently have a liquid-chromatography time-of-flight mass spectrometer, 
making development of a screening and possible quantification method a fairly new idea. With 
the spread of usage of LC-TOF, methods will be needed.  Also, with the rapid emergence of new 
novel psychoactive substances, a screening and potential quantifying method will be beneficial to 
the clinical setting for tentative identification and retrospective analysis of samples possibly 
containing these substances. These drugs have the possibility to be quickly identified and  
13 
 
characterized by LC-TOF even without drug standards. The ability of one instrument to screen 














The purpose of this research was to determine which screening method is superior for 
urine drug analysis. These two techniques compared were immunoassay and Liquid 
Chromatography-Time-of-Flight-Mass Spectrometry (LC-TOF). The first step of this research 
was to create and validate a qualitative method on the LC-TOF. Anonymized results from 
immunoassay were then compared to LC-TOF results of the same sample. These results were 
compared to a validated method on LC-MS/MS to determine reliability of the LC-TOF results. 
3.2 Materials 
The following drug standards were purchased from Cerilliant (Cerilliant Corporation, 
Round Rock, TX) at a concentration of 1 mg/mL in methanol: 6-monoacetylmorphine, 6-
monoacetylmorphine-D6, 7-Aminoclonazepam, 7-Aminoclonazepam-D4, Acetyl fentanyl, Acetyl 
norfentanyl, α-Hydroxyalprazolam, α-Hydroxyalprazolam-D5, Alprazolam, Alprazolam-D5, 
Amphetamine, Benzoylecgonine, Benzoylecgonine-D8, Buprenorphine, Buprenorphine-D4, 
Carisoprodol, Carisoprodol-D7, Clonazepam, Clonazepam-D4, Cocaine, Cocaine-D3, Codeine,  
Codeine-D6, Dextromethorphan, Diazepam, Diazepam-D5, Dihydrocodeine, Dihydrocodeine-
D6, Fentanyl, Flunitrazepam, Flurazepam, Heroin, Heroin-D9, Hydrocodone, Hydrocodone-D6,
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Hydromorphone, Hydromorphone-D6, Lorazepam, Lorazepam-D4, MDA, MDA-D5, 
MDEA, MDEA-D6, MDMA, MDMA-D5, Meperidine, Meperidine-D4, Meprobamate, 
Meprobamate-D7, Methadone, Methadone-D9, Methamphetamine, Methamphetamine-D11, 
Midazolam, Morphine, Morphine-D6, Naloxone,  Naltrexone, Nitrazepam,  Norbuprenorphine-
D3, Nordiazepam, Nordiazepam-D5, Norfentanyl, Norfentanyl-D5, Normeperidine-D4, 
Norpropoxyphene, Norproxyphene-D5, Oxazepam, Oxazepam-D5, Oxycodone, Oxycodone-D6, 
Oxymorphone, Oxymorphone, Oxymorphone-D3, Phenazepam, Phencyclidine (PCP), PCP-D5, 
Phentermine, Phentermine-D5, Propoxyphene, Propoxyphene-D11, Temazepam, Temazepam-
D5, THCA, THCA-D3, and Tramadol. The following drug standards were purchased from 
Cerilliant (Cerilliant Corporation, Round Rock, TX) at a concentration of 100 µg/mL in 
methanol: Amphetamine-D11, Cyclobenzaprine-D3, Dextromethorphan-D3, EDDP, EDDP-D3, 
Fentanyl-D5, Flunitrazepam-D7, Midazolam-D4, Naloxone-D5, Naltrexone-D3, Nitrazepam-D5, 
Norbuprenorphine, Normeperidine, Phenazepam-D4, Sufentanil, Sufentanil-D5, and Tramadol-
D3. Acetyl fentanyl-D5 and Acetyl norfentanyl-D5 were purchased from Cayman Chemical 
(Cayman Chemical, Ann Arbor, Michigan).  
Methanol was purchased from Fisher Scientific (Fisher Scientific, Waltham, MA). 
Formic acid was purchased from EDM (EDM Millipore Corporation, Billerica, MA). HPLC 
grade water was collected from a Barnstead Nanopure water system (Thermo Scientific, 
Waltham, MA). Ammonium formate was purchased from Alfa Aesar (Alfa Aesar, Ward Hill, 
MA). ESI Tuning Mix was purchased from Agilent (Agilent Technologies, Santa Clara, CA), 
Acetonitrile was purchased Fisher Scientific (Fisher Scientific, Waltham, MA). Drug-free urine 
was purchased from UTAK (UTAK Laboratories Inc., Valencia, CA). IMCSzyme and rapid 
hydrolysis buffer were purchased from IMCS (IMCS, Irmo, SC).  




Internal standard was prepared by diluting the deuterated drug standards in methanol to a 
concentration of 1 µg/mL. This process is shown in Table 1. A drug stock solution was created by 
spiking methanol with certified drug standards. Table 2 shows the preparation and final 
concentrations. Analytes listed in Tables 1 and 2 that are not listed in section 3.2 were used in a 
separate method and validation but are not analyzed in this method. A single calibrator for cutoff 
concentrations was made by adding each drug standard, bringing to volume with methanol and 
then diluting by a factor of 1:100 with urine. Table 3 displays this stock preparation. A quality 
control (QC) calibrator at concentrations above the cutoff was made by diluting the drug stock 
solution by a factor of 1:100 with urine. A QC calibrator at concentrations below the cutoff was 
made by diluting the high concentration QC by a factor of 1:10 with urine. Table 4 displays the 
concentrations of these calibrators for each analyte. The calibrator and QC calibrators were stored 
in a freezer at -19℃ with a range of -10℃ to -25℃. 
3.3.2 Tune Mix 
A calibration solution, or tune mix, was made to calibrate the instrument before each use 
and identify the lock masses needed for the instrument. Tune mix was made by adding 50 mL of 
ESI Tuning Mix from Agilent Technologies, 75 mL acetonitrile, 2 mL of a 500 µg/mL caffeine in 
50:50 methanol to water solution, and 250 µL Formic acid in a 250 mL volumetric flask. The 
solution was brought to volume with methanol. 
Table 1. Preparation of 5 mL of internal standard solution. Based off of the stock 
concentrations, a corresponding spike volume was added to reach a final 




















a-Hydroxyalprazolam-D5 5 1 
Alprazolam-D5 5 1 
Amphetamine-D11 50 1 
Benzoylecgonine-D8 5 1 
Buprenorphine-D4 5 1 
Clonazepam-D4 5 1 
Cocaine-D3 5 1 
Codeine-D6 5 1 
Diazepam-D5 5 1 
Dihydrocodeine-D6 5 1 
EDDP-D3 50 1 
Fentanyl-D5 50 1 
Heroin-D9 5 1 
Hydrocodone-D6 5 1 
Hydromorphone-D6 5 1 
MDEA-D6 5 1 
MDMA-D5 5 1 
Methadone-D9 5 1 
Methamphetamine-D11 5 1 
Morphine-D6 5 1 
Norbuprenorphine-D3 5 1 
Norfentanyl-D5 5 1 
Oxycodone-D6 5 1 
PCP-D5 5 1 
THCA-D3 5 1 
Tramadol-13C-D3 50 1 
Total Spike Volume 320 
 
Total Methanol Volume 4680 
 















7-aminoclonazepam 20 10000 








Alprazolam 8 4000 
Amphetamine 8 4000 
Benzoylecgonine 20 10000 
Buprenorphine 4 2000 
Clonazepam 8 4000 
Cocaine 8 4000 
Codeine 20 10000 
Diazepam 8 4000 
Dihydrocodeine 4 2000 
EDDP 80 4000 
Fentanyl 2 1000 
Heroin 20 10000 
Hydrocodone 20 10000 
Hydromorphone 8 4000 
MDEA 8 4000 
MDMA 8 4000 
Methadone 20 10000 
Methamphetamine 20 10000 
Morphine 8 4000 
Norbuprenorphine 40 2000 
Norfentanyl 2 1000 
Oxycodone 8 4000 
Phencyclidine (PCP) 4 2000 
Tramadol 20 10000 
Δ9 THC-COOH 60 30000 
Total Spike Volume 456   
Total Methanol Volume 1544  
Total Volume 2000  
   










7-aminoclonazepam 5 5000 
a-Hydroxyalprazolam 5 5000 
Alprazolam 5 5000 
Amphetamine 5 5000 









Buprenorphine 1 1000 
Clonazepam 5 5000 
Cocaine 5 5000 
Codeine 5 5000 
Diazepam 5 5000 
Dihydrocodeine 5 5000 
EDDP 50 5000 
Fentanyl 0.5 500 
Heroin 5 5000 
Hydrocodone 5 5000 
Hydromorphone 5 5000 
MDEA 5 5000 
MDMA 2 2000 
Methadone 5 5000 
Methamphetamine 5 5000 
Morphine 5 5000 
Norbuprenorphine 10 1000 
Norfentanyl 0.5 500 
Oxycodone 5 5000 
Phencyclidine (PCP) 2.5 2500 
Tramadol 15 15000 
Δ9 THC-COOH 15 15000 
Total Spike Volume 187.5  
Total Methanol Volume 812.5  
Total Volume 1000  
 












Alprazolam 100 20 
Amphetamine 100 20 
Benzoylecgonine 200 40 
Buprenorphine 40 8 










Cocaine 100 20 
Codeine 200 40 
Diazepam 100 20 
Dihydrocodeine 100 20 
EDDP 100 20 
Fentanyl 20 4 
Heroin 100 20 
Hydrocodone 200 40 
Hydromorphone 100 20 
MDEA 100 20 
MDMA 200 40 
Methadone 100 20 
Methamphetamine 200 40 
Morphine 100 20 
Norbuprenorphine 40 8 
Norfentanyl 20 4 
Oxycodone 100 20 
PCP 100 20 
THCA 600 120 





3.4 Sample Preparation 
Twenty urine specimens previously analyzed OSU-CLS with a validated clinical LC-
MS/MS method were used in this research. All calibrators and unknown samples were extracted 
using the following “Dilute and Shoot” method. One hundred µL of calibrator or sample was 
added to polypropylene Eppendorf tubes. Following, 10 µL of IMCSzyme was added along with 
50 µL of rapid hydrolysis buffer and 40 µL internal standard. IMCSzyme is the β-glucuronidase 
used to cleave the glucuronide bond from the drug and the buffer is used to keep the sample at the 
optimal pH for the enzyme activity. The Eppendorf tubes were vortexed for 10 seconds and 
incubated at 60℃ for 30 minutes. The Eppendorf tubes were then taken out of the incubator, and 
50 µL of sample diluent was added. They were then vortexed for 10 seconds and centrifuged at 
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13000 RPM for 10 minutes. After centrifuging, 200 µL of supernatant was transferred to a vial 
insert. The insert was placed in a 2 mL vial and capped. 
3.5 Instrument Parameters and Software 
3.5.1 Liquid Chromatography 
The liquid chromatography portion of the instrument was the Flexar UHPLC pump 
system provided by PerkinElmer® for this research. The column was a Restek Raptor™ Biphenyl 
2.7 µm. The column was 100x2.1mm in size. This column utilized the EXP® connect holder and 
EXP® guard cartridge from Restek. This column was used to achieve adequate analyte 
separation. The autosampler was kept at a temperature of 20℃ with a tolerance of +/- 2℃. The 
injection volume was 15 µL. Mobile phase A used with the pump was 2mM Ammonium formate 
and 0.1% Formic acid in HPLC grade water. Mobile phase B used was 2mM Ammonium formate 
and 0.1% Formic acid in HPLC grade methanol. The UHPLC pump gradient was designed to 
separate the analytes efficiently as well as coeluting analytes. Total pump run time was 6.5 
minutes. After each run, there was a 3-minute equilibration time to return to starting parameters. 
Table 5 displays the pump gradient.  
Table 5. Flexar UHPLC pump gradient profile of mobile phases A and B. 
Gradient Profile   
Step Minutes mL/min %A %B 
0 1.0 0.45 98.0 2.0 
1 0.5 0.45 98.0 2.0 
2 0.5 0.45 65.0 35.0 
3 1.0 0.45 65.0 35.0 
4 3.0 0.45 5.0 95.0 
5 1.0 0.45 5.0 95.0 
6 0.1 0.45 98.0 2.0 





3.5.2 Time-of-Flight Mass Spectrometer 
The AxION® 2 Time-of-Flight Mass Spectrometer was provided by PerkinElmer® for 
this research. Each batch run used the same parameters. Table 6 displays the mass spectrometer 
parameters for positive mode. The calibration solution in the calibration vial was used to calibrate 
the instrument before each use and find the lock masses used for the instrument. Table 7 displays 
the optics parameters within the source for each run.  
Table 6. Positive mode parameters for time-of-flight mass spectrometer. 
Positive Mode    
Cylinder  -3500 V Dry Gas Flow 15 L/min 
Endplate -4800 V Dry Gas Heat 350℃ 
Capillary Entrance -5800 V Right Nebulizer Gas 80 PSI 
Endplate Heater Medium Left Nebulizer Gas 40 PSI 
Diverter Waste Calibration Vial Left 
 
Table 7. Optics parameters for positive mode for time-of-flight mass spectrometer. 
Optics    
Capillary Exit 140 V RF Voltage 500 V 
Skimmer 25 Offset Voltage 14.4 V 
DAU 4000 V   
 
A time-of-flight mass spectrometer utilizes an exact mass feature up to four decimal 
places. These masses are used to identify the analytes being tested in the instrument and find the 
correct retention times of each analyte. Table 8 contains the list of analytes with corresponding 
formulas, exact masses, and retention times. 















D6 C19H15NO4D6 334.1920 2.863 
7-aminoclonazepam C15H12ClN3O 286.0742 3.661 
7-Aminoclonazepam-D4 C15H8ClN3OD4 290.0993 3.644 
a-Hydroxyalprazolam C17H13ClN4O 325.0850 4.779 
a-Hydroxyalprazolam-D5 C17H8ClN4OD5 330.1164 4.767 
Alprazolam C17H13ClN4 309.0902 5.03 
Alprazolam-D5 C17H8ClN4D5 314.1215 5.015 
Amphetamine C9H13N 136.1121 2.318 
Amphetamine-D11 C9H2ND11 147.1811 2.241 
Benzoylecgonine C16H19NO4 290.1387 3.488 
Benzoylecgonine-D8 C16H11NO4D8 298.1889 3.458 
Buprenorphine C29H41NO4 468.3108 4.11 
Buprenorphine-D4 C29H37NO4D4 472.3359 4.102 
Clonazepam C15H10ClN3O3 316.0483 4.656 
Clonazepam-D4 C15H6ClN3O3D4 320.0735 4.643 
Cocaine C17H21NO4 304.1543 3.61 
Cocaine-D3 C17H18NO4D3 307.1732 3.606 
Codeine C18H21NO3 300.1594 2.845 
Codeine-D6 C18H15NO3D6 306.1971 2.826 
Diazepam C16H13ClN2O 285.0789 5.203 
Diazepam-D5 C16H8ClN2OD5 290.1103 5.19 
Dihydrocodeine C18H23NO3 302.1751 2.812 
Dihydrocodeine-D6 C18H17NO3D6 308.2127 2.794 
EDDP C20H23N 278.1982 4.367 
EDDP-D3 C20H21ND3 282.2170 4.3620 
Fentanyl C22H28N2O 337.2274 4.093 
Fentanyl-D5 C22H23N2OD5 342.2588 4.081 
Heroin C21H23NO5 370.1649 3.535 
Heroin-D9 C21H14NO5D9 379.2214 3.516 
Hydrocodone C18H21NO3 300.1594 3.005 
Hydrocodone-D6 C18H15NO3D6 306.1971 2.99 
Hydromorphone C17H19NO3 286.1438 2.4 
Hydromorphone-D6 C17H13NO3D6 292.1814 2.374 
MDEA C12H17NO2 208.1332 3.128 
MDEA-D6 C12H11NO2D6 214.1709 3.116 
MDMA C11H15NO2 194.1176 2.919 
MDMA-D5 C11H9NO2D5 198.1411 2.91 








Methadone-D9 C21H18NOD9 319.2730 4.571 
Methamphetamine C10H15N 150.1277 2.647 
Methamphetamine-D11 C10H4ND11 161.1968 2.59 
Morphine C17H19NO3 286.1438 2.142 
Morphine-D6 C17H13NO3D6 292.1814 2.12 
Norbuprenorphine C25H35NO4 414.2639 3.785 
Norbuprenorphine-D3 C25H32NO4D3 417.2827 3.779 
Nordiazepam-D5 C15H6ClN2OD5 276.0947 4.825 
Norfentanyl C14H20N2O 233.1648 3.276 
Norfentanyl-D5 C14H15N2OD5 238.1962 3.258 
Oxycodone C18H21NO4 316.1543 2.947 
Oxycodone-D6 C18H15NO4D6 322.1920 2.931 
PCP-D5 C17H20ND5 249.2374 4.155 
Phencyclidine (PCP) C17H25N 244.2060 4.171 
THCA-D3 C22H27O4D3 348.2270 5.39 
Tramadol HCl C16H25NO2 264.1958 3.362 
Tramadol-13C-D3 C15H22NO2(13)CD3 268.2180 3.349 
Δ9 THC-COOH C22H30O4 345.2128 5.395 
 
            3.5.3 Software 
            The software used in conjunction with the time-of-flight was Chromera® version 3.4.4. 
Chromera® is licensed to PerkinElmer®. 
3.6 Validation 
A qualitative method validation was performed to ensure the viability of the method. 
Included in the validation was limit of detection, matrix effects, sample stability, process sample 
stability, and interference. 
3.6.1 Limit of Detection 
Limits of detection are the lowest and highest concentrations of analytes that the 
instrument can accurately see and identify. Lower limits of detection (LLOD) are the lowest 
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concentrations the instrument can identify. In this research, the LLOD were determined from the 
analyte cutoffs for the EasyRA® as well as relevant concentrations in the pain management 
community. The cutoffs for the calibrators (not including the cross-reactive analytes) for the 
EasyRA® can be seen in Table 9. 












3.6.2 Matrix Effects 
Matrix effects studies are conducted to discover if there are any unwanted effects caused 
by the urine matrix. Ten urine samples were spiked as the high concentration QC by a dilution of 
1:100 of the stock calibrator with urine. The urine samples from different sources were extracted 
and prepared as described above. The peak areas of each sample for each analyte were compared 
to a blank urine sample. The comparisons were given a percentage to determine effects. If the 
percentage was above 100, there may have been ion enhancement. If the percentage was below 
100, there may have been ion suppression.  (Partridge et al.) 
3.6.3 Sample Stability 
Sample stability is run to determine the effects of storage on each analyte. Fifteen 
samples are prepared and left in 3 different storage conditions. The samples were then run in sets 
of 3, 1 of each storage condition, over a period of 7 days. Five samples were left sitting on the 
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laboratory bench, 5 were stored in the freezer, and 5 were stored in the refrigerator. The peak 
areas of each analyte for each sample was recorded and compared to determine which storage 
condition had the least amount of effects (i.e.: analyte deterioration) on the sample. 
3.6.4 Process Sample Stability  
Process sample stability is used to determine sample stability within the instrument on the 
autosampler. It consists of running an individual sample on the instrument over a period of 3 
days. The first injection is considered the “baseline” and run on the first day. The second run is 
done at 24 hours from the time of the first injection. The third run is done at 48 hours from the 
time of the first injection. 
3.6.5 Interference 
Interference is used to determine if any other analytes in a sample are going to interfere 
with the analyte of concern. Two mixes were made which each contain common analytes seen 
within samples. Interference uses 6 samples, 4 urine and 2 water. All samples are spiked as the 
high QC calibrator. Because the QC is made from a stock of multiple analytes, the analytes not 
being used in this method are also considered to be interference drugs. Two of the urine samples 
have one of the interference mixes added to them while the other two have the second mix added. 
The water samples do not have the mix added. The samples are then extracted as usual. The 
analyte areas are compared to determine if interference is present. Table 10 shows the list of 
drugs in each mix solution.  
Table 10. Interference mix analytes used for validation. 
Interference Mix 1 Interference Mix 2 
(-)-Nicotine Ibuprofen 
Acetaminophen Naproxen 
Acetyl fentanyl Acetyl fentanyl 
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Interference Mix 1 Interference Mix 2 
Acetyl Fentanyl-D5 Acetyl Fentanyl-D5 
Acetyl norfentanyl Acetyl norfentanyl 
Acetyl Norfentanyl-D5 Acetyl Norfentanyl-D5 































































4.1.1 Limit of Detection 
The lower limits of detection (LLOD) were determined from the immunoassay cutoff 
concentrations and significant clinical pain management concentrations used in the OSU-CLS 
clinical method. The cutoffs were intended to be lower than immunoassay to avoid not being able 
to identify samples with a much lower concentration. Fentanyl and Norfentanyl had a LLOD of 5 
ng/mL. The following drug analytes had a concentration of 10 ng/mL: 6-MAM, Buprenorphine, 
and Norbuprenorphine. MDMA had a concentration of 20 ng/mL and PCP had a concentration of 
25 ng/mL. The following drug analytes had a concentration of 50 ng/mL: 7-Aminoclonazepam, 
α-Hydroxyalprazolam, Alprazolam, Amphetamine, Benzoylecgonine, Clonazepam, Cocaine, 
Codeine, Diazepam, Dihydrocodeine, EDDP, Heroin, Hydrocodone, Hydromorphone, MDEA, 
Methadone, Methamphetamine, Morphine, and Oxycodone. Tramadol and THCA had a LLOD 
concentration of 150 ng/mL. Table 11 displays the LLODs for the analytes used in this research. 
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Phencyclidine (PCP) 25 
Tramadol 150 







4.1.2 Matrix Effects 
The analytes along with their matrix effects results can be seen in Table 12. A percentage 
above 100% suggests ion enhancement due to the matrix while a percentage below 100% 
suggests ion suppression due to the matrix. 































Phencyclidine (PCP) 113.06 
Tramadol 100.62 





4.1.3 Sample Stability 
The results of sample stability should show an increase of percentage difference due to 
the peak areas decreasing over time in relation to the “Day 0” peak for each analyte. This 
expected increase is due to the degradation of the analytes during storage. Results show that this 
research is not consistent with the expected trend. Because the percentages should have been in a 
consistent increase for the entire duration due to consistent degradation over time, it is 
hypothesized that the anomaly in the process was due to an improvement of the instrument’s 
performance after a period of non-use. These percent differences can be seen in Table 13. 
Table 13. Percent differences for each analyte and each storage condition over a period 
of 7 days. 
 
  Percent Difference from Day 0 Area 
Analyte Storage Day 2 Day 3 Day 5 Day 6 Day 7 
6-MAM 
Freezer -8.67 -10.19 -5.60 5.09 -2.68 
Refrigerator -5.61 -9.61 -43.43 -3.60 1.20 
Bench 13.69 -21.30 -19.4 -16.77 -14.32 
7 amino 
Freezer -14.25 -19.62 -15.11 -3.46 -1.22 
Refrigerator -10.97 -16.90 -14.84 -6.71 -3.45 
Bench -2.60 -10.53 -1.01 9.48 16.97 
a-Hydroxyalprazolam 
Freezer -23.75 -28.43 -23.92 -15.88 -11.67 
Refrigerator -19.25 -23.93 -24.69 -10.22 -11.22 
Bench -15.32 -26.06 -24.14 -15.27 -8.65 
Alprazolam 
Freezer -15.08 -22.02 -22.31 -8.59 -11.77 
Refrigerator -9.93 -17.54 -17.36 -12.54 -10.97 
Bench -15.99 -22.88 19.71 -12.70 -8.85 
Amphetamine 
Freezer -11.04 -12.27 -6.49 -1.07 2.92 
Refrigerator -11.60 -8.78 -6.65 4.98 11.77 
Bench -1.10 -14.27 -4.68 3.44 15.12 
Benzoylecgonine 
Freezer -14.57 -22.61 -17.62 -9.04 -6.31 
Refrigerator -11.28 -15.91 -13.99 -6.33 -4.66 
Bench -6.23 -19.35 -14.62 -7.27 -2.05 
Buprenorphine 
Freezer -28.64 -29.44 -25.44 -20.69 -19.35 
Refrigerator -24.23 -26.03 -25.72 -19.77 -16.90 
Bench -26.55 -26.70 -25.06 -19.14 -18.03 
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  Percent Difference from Day 0 Area 
Analyte Storage Day 2 Day 3 Day 5 Day 6 Day 7 
Clonazepam 
Freezer -19.34 -21.14 -19.96 -10.00 -11.01 
Refrigerator -14.59 -19.07 -19.71 -11.59 -7.71 
Bench -18.90 -13.84 -18.27 -5.75 -11.38 
Cocaine 
Freezer -21.68 -29.18 -23.87 -16.67 -10.13 
Refrigerator -18.50 -26.45 -25.71 -16.22 -8.84 
Bench -17.01 -24.54 -19.09 -9.22 -3.38 
Codeine 
Freezer -14.00 -19.80 -19.42 -6.28 -8.76 
Refrigerator -9.03 -15.97 -15.40 -8.63 -6.65 
Bench -10.76 -16.59 -17.12 -7.51 -3.52 
Diazepam 
Freezer -16.16 -23.63 -20.43 -9.26 -7.82 
Refrigerator -11.81 -17.75 -18.42 -8.00 -6.01 
Bench -7.51 -21.09 -13.70 -7.17 -3.69 
Dihydrocodiene 
Freezer -19.87 -19.48 -19.93 -11.64 -9.2 
Refrigerator -14.09 -22.33 -20.19 -6.59 -7.44 
Bench -11.38 -21.19 -17.74 -8.46 -5.57 
EDDP 
Freezer -18.32 -23.54 -20.39 -10.58 -8.80 
Refrigerator -11.99 -20.53 -20.38 -12.22 -8.35 
Bench -12.78 -21.78 -18.53 -11.74 -5.85 
Fentanyl 
Freezer -18.11 -24.47 -20.87 -8.81 -7.27 
Refrigerator -14.65 -19.27 -20.27 -13.30 -6.10 
Bench -18.41 -22.27 -18.29 -8.89 -4.03 
Heroin 
Freezer -28.32 -35.05 -30.73 -21.67 -20.61 
Refrigerator -22.55 -32.83 -28.81 -20.59 -15.90 
Bench -17.81 -23.78 -16.49 -4.83 -0.01 
Hydrocodone 
Freezer -14.33 -19.88 -19.50 -6.59 -8.90 
Refrigerator -9.56 -14.16 -14.68 -7.88 -5.50 
Bench -10.33 -15.08 -16.08 -6.86 -4.35 
Hydromorphone 
Freezer -16.91 -24.71 31.84 -11.27 -12.2 
Refrigerator -14.59 -23.56 -17.95 -10.04 -4.97 
Bench -12.93 -19.38 -15.61 -8.59 -6.16 
MDEA 
Freezer -18.81 -24.82 -18.41 -12.72 -7.49 
Refrigerator -11.91 -17.74 -22.08 -10.56 -4.81 
Bench -8.89 -22.53 -19.94 -9.77 -3.30 
MDMA 
Freezer -14.51 -19.48 -15.73 -10.33 -7.08 
Refrigerator -11.64 -15.97 -15.28 -5.02 -0.82 
Bench -8.83 -17.97 -12.79 -1.81 -1.71 
Methadone 
Freezer -20.69 -29.44 -26.53 -16.65 -5.18 
Refrigerator -17.46 -26.75 -26.40 -14.23 -9.52 
Bench -14.09 -26.52 -23.89 -16.18 -3.76 
Methamphetamine 
Freezer -13.45 -20.22 -15.43 -3.41 -1.63 
Refrigerator -3.51 -16.37 -15.89 -0.03 -1.24 
Bench -2.90 -17.40 -12.69 -1.28 3.29 
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  Percent Difference from Day 0 Area 
Analyte Storage Day 2 Day 3 Day 5 Day 6 Day 7 
Morphine 
Freezer -16.12 -24.02 -18.20 -9.95 -12.89 
Refrigerator -15.80 -21.77 -16.96 -11.19 -7.41 
Bench -12.16 -18.74 -16.96 -7.07 -4.82 
Norbuprenorphine 
Freezer -25.02 -25.78 -23.36 -17.47 -18.65 
Refrigerator -22.02 -24.26 -23.73 -15.59 -12.46 
Bench -19.37 -23.60 -20.59 -17.53 -14.16 
Norfentanyl 
Freezer -12.93 -18.39 -16.76 -10.04 -2.06 
Refrigerator -6.84 -15.05 -15.89 -0.21 1.80 
Bench 4.07 -19.53 -14.99 -3.38 6.71 
Oxycodone 
Freezer -19.44 -20.40 -21.86 -9.64 -10.01 
Refrigerator -12.44 -18.60 -18.77 -8.88 -9.70 
Bench -14.30 -21.11 -18.42 -8.34 -4.54 
Phencyclidine (PCP) 
Freezer -19.19 -25.69 -23.64 -12.56 -7.51 
Refrigerator -11.95 -22.38 -22.06 -12.79 -12.35 
Bench -10.75 -24.81 -18.68 -12.17 -5.18 
Tramadol 
Freezer -18.17 -23.18 -23.61 -7.41 -5.53 
Refrigerator -10.20 -20.57 -21.64 -9.33 -5.00 
Bench -11.79 -23.19 -19.91 -8.58 2.61 
Δ9 THC-COOH 
Freezer -16.04 -23.15 -19.83 -8.66 -16.41 
Refrigerator -4.48 -24.86 -16.68 -12.32 -7.65 
Bench -17.13 -19.88 -18.62 -13.60 -11.80 
 
 
4.1.4. Process Sample Stability 
The results of process sample stability should show an increase of percentage difference 
due to the peak areas decreasing over time in relation to the baseline peak for each analyte. The 
results from the single sample run on the instrument over a period of 3 days are seen in Table 14. 
The entries labeled “N/A” refer to a lack of peak identification by the TOF. 
Table 14. Process sample stability results showing percent difference from baseline 
sample 
 Percent Difference from Baseline 
Analyte  24 hrs 48 hrs 
6-monoacetylmorphine (6-
MAM) -25.60% -25.16% 
7-aminoclonazepam -1.71% -2.51% 
a-Hydroxyalprazolam -2.24% -0.22% 
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 Percent Difference from Baseline 
Analyte  24 hrs 48 hrs 
Alprazolam -0.46% 1.18% 
Amphetamine -4.36% 1.52% 
Benzoylecgonine -3.43% -3.06% 
Buprenorphine -0.58% -0.35% 
Clonazepam -4.21% -4.41% 
Cocaine -3.15% -0.76% 
Codeine 1.77% 5.23% 
Diazepam 1.04% 1.60% 
Dihydrocodeine 2.50% 2.74% 
EDDP -3.30% -10.88% 
Fentanyl -3.50% -2.75% 
Heroin 0.98% -2.14% 
Hydrocodone 0.65% 1.62% 
Hydromorphone 10.16% 0.49% 
MDEA 0.76% -0.43% 
MDMA 6.50% N/A 
Methadone 0.28% -0.87% 
Methamphetamine -0.10% -1.85% 
Morphine -0.18% -3.79% 
Norbuprenorphine N/A N/A 
Norfentanyl -8.59% 50.00% 
Oxycodone 2.10% 2.81% 
Phencyclidine (PCP) -3.30% -0.51% 
Tramadol 0.82% -1.29% 
Δ9 THC-COOH 50.00% 50.00% 
 
4.1.5 Interference 
The first mix used in interference contained (-)-Nicotine, Acetaminophen, and Caffeine. 
The second mix contained Ibuprofen, Naproxen, and R,R(-)-Pseudoephedrine. Table 15 displays 
the percent difference of area between the two injections of each mix solution. A positive 
percentage suggests the analyte would still be present in the sample but the interference mix is 
causing an enhancement. A negative percentage suggests the analyte would still be present in the 
sample but the interference mix is causing a suppression. 
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Table 15. Interference mix percent differences between both sample injections. Positive 
percentage suggests ion enhancement while negative percentage suggest ion suppression. 
 
Analyte 
Mix 1 Percent 
Difference (%) 
Mix 2 Percent 
Difference (%) 
6-monoacetylmorphine (6-
MAM) 21.85 9.23 
7-aminoclonazepam 8.20 -3.15 
a-Hydroxyalprazolam 7.56 -9.34 
Alprazolam 17.42 11.92 
Amphetamine 31.16 16.01 
Benzoylecgonine 9.05 -2.64 
Buprenorphine 0.98 -12.14 
Clonazepam 28.72 9.23 
Cocaine 3.37 -2.04 
Codeine 10.52 7.92 
Diazepam -0.81 -5.49 
Dihydrocodeine 3.27 7.95 
EDDP 6.56 2.60 
Fentanyl 24.65 3.45 
Heroin 8.99 -0.33 
Hydrocodone 15.22 9.80 
Hydromorphone 6.81 -29.25 
MDEA 13.49 7.07 
MDMA 13.04 16.12 
Methadone 2.82 -4.89 
Methamphetamine 4.50 -0.64 
Morphine 12.54 -3.57 
Norbuprenorphine 27.08 9.55 
Norfentanyl 12.10 -39.76 
Oxycodone 25.85 17.28 
Phencyclidine (PCP) -9.14 -18.88 
Tramadol 0.70 8.87 









For analysis of unknown samples, 20 samples previously screened with immunoassay 
and confirmed with quantitative LC-MS/MS were extracted using the previously described 
“Dilute and Shoot” method. All 20 samples were also run on a liquid chromatography-tandem 
mass spectrometer with a clinically validated confirmation method to determine if the time-of-
flight was providing valid results. Table 16 displays the results for comparison. 
Table 16. Unknown sample results for Immunoassay, LC-TOF, and LC-MS/MS analysis. 
Sample Immunoassay Result TOF Result LC-MS/MS Result 
1 Negative Negative Negative 
2 Negative Oxycodone, Tramadol Tramadol 
3 Negative Oxycodone, Tramadol Tramadol 
4 Opiate Hydrocodone, Dihydrocodeine Hydrocodone 
5 Opiate Oxycodone Oxycodone 
6 Negative Oxycodone, Tramadol Tramadol 
7 Negative Oxycodone Oxycodone 
8 Opiate Oxycodone, Dihydrocodeine Oxycodone 










Sample Immunoassay Result TOF Result LC-MS/MS Result 
11 Negative Tramadol Tramadol 
12 Opiate Dihydrocodeine, Oxycodone  Oxycodone 
13 Opiate Dihydrocodeine, Hydrocodone Hydrocodone 
14 Negative Negative Negative 
15 Negative Oxycodone, Tramadol  Tramadol 
16 Opiate Morphine Morphine  
17 Opiate Hydrocodone Hydrocodone 













Example chromatograms are shown below in Figures 3 and 4. Figure 3 displays an entire 








Figure 4. Chromatogram displaying the individual analyte, morphine, for sample 16. 
 
4.4 Statistics 
The number of true positives, true negatives, false positives, and false negatives were 
determined for both immunoassay results and time-of-flight results for each drug class A true 
positive (TP) is a result that detects the presence of a drug that is truly present. A true negative 
(TN) is a result that does not detect a drug when a drug is not present. A false positive (FP) is a 
result that detects a drug when the drug is not present. A false negative (FN) is a result that does 
not detect a drug when a drug is present.  




The performance of each instrument, EasyRA® and AxION® 2, was done by evaluating 
the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. 
Sensitivity refers to the number of TP as a percent of all positives. Specificity refers to the 
number of TN as a percent of all negatives. Positive predictive value (PPV) is the number of 
samples with positive results that are TP expressed as a percentage. Negative predictive value 
(NPV) is the number of samples with negative results that are TN expressed as a percentage. 
Accuracy is the number of all correctly identified results, classified in a percentage. Table 17 
shows the total number of TP, TN, FP, and FN for both the time-of-flight instrument and the 
immunoassay instrument. Sensitivity, specificity, PPV, NPV, and accuracy results can be seen in 
Table 18. False negatives for immunoassay include Tramadol and benzodiazepine data, which 
were present in the specimens but not tested for in the immunoassay panels. 
Table 17. Total number of true positives, true negatives, false positives, and false 
negatives based on drug class for the time-of-flight and immunoassay. 
  TP TN FP FN 
TOF 20 156 4 1 
IA 11 140 0 9 
  
Table 18. Sensitivity, specificity, PPV, NPV, and accuracy results of immunoasssay and 
time-of-flight 
TOF IA 
sensitivity 0.95 sensitivity 0.55 
specificity 0.98 specificity 1.00 
PPV 0.83 PPV 1.00 
NPV 0.99 NPV 0.94 









DISCUSSIONS AND CONCLUSIONS 
 
5.1 Validation 
The validation of this method was conducted under the standard practices for qualitative 
method validation created by the Scientific Working Group for Forensic Toxicology (SWGTOX). 
Most of the results were within recommended guidelines. Those that were not include matrix 
effects for α-Hydroxyalprazolam (130.35%), Amphetamine (307.54%), EDDP (143.90%), 
MDMA (61.40%), and Morphine (41.61%). The recommended percentage for matrix effects is 
+/- 30%. For sample stability, the inconsistencies of percentages in the analysis were 
hypothesized to be due to an improvement of the instrument’s performance over the first few 
days of use after a period of non-use. All samples appeared to be stable for up to seven days in all 
evaluated storage conditions. 
5.2 Correlation 
When the time-of-flight instrument and the immunoassay instrument were compared to 
the liquid chromatography-tandem mass spectrometer at OSU-CLS, multiple false and true results 
were found. Based on the drug classes, the EasyRA® produced no false positive results, nine 
false negative results, eleven true positive results, and 140 true negative results for the drug class 
reference standards used. The AxION® 2 produced four false positive results, one false negative 
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result, twenty true positive results, and 156 true negative results. For the LC-TOF, sensitivity was 
calculated to be 95%, specificity was 98%, PPV was 83%, NPV was 99%, and accuracy was 
97%. For the immunoassay, sensitivity was 55%, specificity was 100%, PPV was 100%, NPV 
was 94%, and accuracy was 94%. The two instruments were found to be statistically different 
based on a categorical statistical analysis performed in Microsoft® Office Excel. 
5.3 Liquid Chromatography Time-of-Flight Mass Spectrometer 
This research developed and validated a pain panel screening method on a liquid 
chromatography time-of-flight mass spectrometer. The method was applied to twenty unknown 
urine samples which were then compared to a liquid chromatography-tandem mass spectrometer 
to further verify the results found on the LC-TOF. LC-TOF was determined to have a higher 
sensitivity and overall accuracy than immunoassay. It was able to identify certain drugs present in 
a sample as opposed to a drug class as found with the immunoassay instrument. It was also 
determined to have a lower false negative rate than immunoassay.  
5.4 Solutions 
Immunoassay instruments use certain calibrators to identify drug classes. These 
calibrators are specific and if a calibrator is not being used for a certain drug, the screen will 
produce a negative result. The immunoassay used in this study did not use calibrators specific to 
Tramadol. Each Tramadol positive found in the LC-TOF screen had a negative screen for the 
immunoassay. Not having every possible calibrator could lead to missed analytes. Having these 
calibrators and having to constantly purchase and replace them leads to a costly investment of the 
immunoassay instrument. LC-TOF does not require these stock calibrators but laboratory-made 
QC calibrators of a low and high concentration, a calibrator of a LLOD concentration, mobile 
phase, and needle rinse for the instrument. Certified drug standards need to be purchased; 
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however, a single vial of one milliliter can last for an extended period of time and has a shelf life 
of multiple years upon purchase.  
5.5 Conclusions 
It was determined that the LC-TOF is more sensitive than immunoassay, and it was 
possible to design the LC-TOF qualitative screen to look for many specific compounds that 
would require quite a few immunoassay panels. While the positive predictive value was not ideal 
at only 83% (due to false positives), it seemed that this was better than the false negatives 
associated with immunoassay.  In terms of costs, the TOF instrument has a higher initial cost and 
maintenance, but the reagents are much less than immunoassay. So, while it was felt that LC-TOF 
performed better than immunoassay, laboratories will need to determine which screening method 
is best suited for their needs.  
In the future, a quantitative method can be developed and validated to complement the 
qualitative method of the LC-TOF. As of now, LC-TOF is not typically used for quantitation. It is 
not considered the ideal instrument for that application due to its difficulties of accurate 
concentrations and the possibility of saturation of the detector of the high concentration 
calibrators.  An extended drug panel could be created to further identify drugs present within 
samples. Some of these drugs could include novel psychoactive substances such as fentanyl 
analogs, spice compounds, and cathinones, also known as bath salts.  
In summary, LC-TOF could be an acceptable alternative to immunoassay screening. It is 
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